Titan Pharmaceuticals (NSDQ:TTNP) and Opiant Pharmaceuticals(NSDQ:OPNT) announced this week that the companies are partnering to develop a subcutaneous implant to deliver an opioid antagonist.
The pair said they plan to conduct a feasibility assessment of such an implant using Titan’s ProNeura sustained release technology. The goal of their collaboration is to devise a way to prevent opioid relapse and overdose in people with opioid use disorder, the companies said, by delivering therapeutic levels of an opioid antagonist for six months at a time.
Get the full story at our sister site, Drug Delivery Business News.
The post Titan, Opiant partner to develop subcutaneous implant for opioid use disorder appeared first on MassDevice.
from MassDevice http://ift.tt/2xkRDUf
Cap comentari:
Publica un comentari a l'entrada